Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Ethn Dis ; 32(1): 61-68, 2022.
Article in English | MEDLINE | ID: mdl-35106045

ABSTRACT

Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person committee dedicated to developing strategies to increase clinical research participation. To help improve the recruitment and retention of patients of color, this article chronicles our efforts to tangibly address the clinical research barriers at the system, study, and patient levels over the last four years. These efforts are one of the initial steps to fully realize the promise of personalized health care and provide increased patient benefit at less cost to society. Instead of simply acknowledging the problem, here we illuminate the collaborative and multilevel strategies that have been effective in delivering meaningful progress for patients.

2.
J Investig Med ; 66(3): 653-660, 2018 03.
Article in English | MEDLINE | ID: mdl-29151042

ABSTRACT

The study aimed to assess the economic burden, health-related quality of life (HRQoL), and acromegaly treatment satisfaction in the USA. A web-based, cross-sectional survey was distributed to members of Acromegaly Community. Data related to comorbidities, treatment patterns, and treatment satisfaction were collected. The costs over the past 3 months included out-of-pocket cost, sick leave, leave of absence, direct loss of job due to acromegaly, unemployment, assistance to perform household chores, and family member loss of income. The HRQoL was assessed by Acromegaly Quality of Life (AcroQoL) and EQ-5D-3L questionnaires. Among 106 patients who completed the survey (mean age: 46 years, female: 76.4%), 44.3% presented with ≥5 comorbidities, and 90.6% reporting acromegaly-related symptoms. Compared with the low-symptom group 0-3 (n=41), the 4+ symptoms group (n=65) was more likely to have depression (OR=2.3, 95% CI 1.1 to 5.2) and cardiovascular disease (OR=5.8, 95% CI 2.0 to 16.7), and experienced higher costs (loss of job: $8874 vs $1717, P=0.02; unemployment disability: $17,102 vs $429, P=0.003; household chores: $2160 vs $932, P=0.0003; family members' income loss: $692 vs $122, P=0.03). The high-symptom group had lower HRQoL scores, compared with the low-symptom group (EQ-5D-3L: 0.53 vs 0.75, P<0.0001; AcroQoL: 27 vs 56, P<0.0001). Only 55.7% among patients requiring injections for acromegaly were satisfied. Patients with acromegaly who presented with multiple acromegaly-related symptoms were evidenced to have experienced higher economic burden and poorer quality of life than patients with the same diagnosis but fewer symptoms. The low rate of treatment satisfaction warrants need for further studies.


Subject(s)
Acromegaly/epidemiology , Cost of Illness , Personal Satisfaction , Quality of Life , Adolescent , Adult , Demography , Female , Humans , Male , Middle Aged , Patient-Centered Care , Young Adult
3.
J Manag Care Spec Pharm ; 21(12): 1106-12, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26679960

ABSTRACT

BACKGROUND: Acromegaly is a chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels most often caused by a pituitary adenoma. Clinical presentation of the disease includes coarsening of the facial features, soft-tissue swelling of the hands and feet, and overgrowth of the frontal skull and protrusion of the jaw, as well as joint symptoms. Acromegaly is associated with several comorbidities, including diabetes, cardiovascular disease, and arthropathy, which, if left untreated, can lead to early mortality. Surgery to remove the adenoma is the first-line treatment for many patients, but more than 50% of patients will require additional pharmacologic or radiation therapy. OBJECTIVES: To (a) determine the clinical and economic burden of illness among patients with acromegaly using administrative claims data from a large, commercially insured population in the United States and (b) estimate the most frequent acromegaly-related comorbidities and health care resource utilization and costs among these patients. METHODS: This retrospective, observational cohort study used administrative claims data from the HealthCore Integrated Research Database, containing a geographically diverse spectrum of longitudinal claims data from the largest database of commercially insured patients in the United States. Patients were aged ≥ 20 years and fulfilled ≥ 1 of the following criteria during the intake period (March 31, 2008-July 31, 2012): ≥ 2 independent diagnostic codes for acromegaly, ≥ 1 acromegaly diagnosis code and ≥ 1 acromegaly-related procedure code, or ≥ 1 acromegaly diagnosis code and ≥ 1 medical claim for acromegaly-related therapy. The index date was defined as the date of the first medical claim for acromegaly within the intake period. Assessed outcomes included prevalence of acromegaly diagnosis and incidence of new acromegaly diagnoses during the study period (January 1, 2008-July 31, 2013), acromegaly-related comorbidities, and pharmacotherapy use. Because 2008 and 2012 data were incomplete, incidence rates were only reported for 2009, 2010, and 2011. Total and acromegaly-related health care resource utilization and annual health care costs were analyzed during a 12-month post-index observational period. RESULTS: In total, 757 patients with acromegaly met the selection criteria for this study, with a mean age of 49.3 years (53.6% female). The total prevalence of acromegaly was 41.7 cases per million. Acromegaly incidence was 15.0, 13.3, and 9.5 cases per million in 2009, 2010, and 2011, respectively. The top 5 acromegaly-related comorbidities were hypertension, diabetes, hypothyroidism, arthropathy/arthralgia/synovitis, and sleep apnea. During the study period, 51% of patients (n = 385) used acromegaly-related pharmacologic therapy, with the most common being cabergoline and octreotide (used by 12.4% and 12.2% of patients, respectively). Overall, 18.8% of patients incurred an acromegaly-related inpatient stay; 97.0% used outpatient services other than emergency room (ER) or physician visits; 74.8% had a physician office visit; and 1.8% visited the ER for acromegaly-related reasons. In the 12-month post-index period, 37.0% of patients filed claims for acromegaly-related prescription drugs, and patients with greater than 1 claim had an average of 7.6 prescriptions. The most expensive acromegaly-related costs in this study population were inpatient hospitalizations ($6,754) and prescription drugs ($6,147). CONCLUSIONS: Consistent with previous studies, this study confirms that acromegaly is a rare condition associated with multiple comorbidities. Notably, 18.8% of this study population required an inpatient hospital admission during the 12-month post-index period, possibly because of severe comorbidities. Because acromegaly-related costs were driven by hospitalizations and pharmacotherapy, improved management of the disease may reduce the clinical and economic burden experienced by patients with acromegaly.


Subject(s)
Acromegaly/economics , Acromegaly/therapy , Commerce/economics , Health Care Costs , Health Resources/economics , Insurance, Health/economics , Process Assessment, Health Care/economics , Acromegaly/diagnosis , Acromegaly/epidemiology , Adult , Aged , Ambulatory Care/economics , Comorbidity , Databases, Factual , Drug Costs , Emergency Service, Hospital/economics , Female , Health Resources/statistics & numerical data , Hospital Costs , Humans , Incidence , Male , Middle Aged , Office Visits/economics , Prevalence , Retrospective Studies , Time Factors , Treatment Outcome , United States/epidemiology , Young Adult
4.
Am J Cardiol ; 115(5): 557-62, 2015 Mar 01.
Article in English | MEDLINE | ID: mdl-25727079

ABSTRACT

Lipoprotein levels are currently recognized as independent risk factors for long-term cardiovascular events after acute myocardial infarction (AMI). During the acute-phase reaction after AMI, previous studies have reported trends of decreased low-density lipoprotein cholesterol (LDL-C), increased triglycerides, and variable high-density lipoprotein cholesterol (HDL-C) levels. However, the association between LDL-C and HDL-C levels and in-hospital mortality has not been well established following AMI. The relationship between lipid levels and in-hospital all-cause mortality in 115,492 patients hospitalized for AMI (July 2002 to December 2006), registered in the National Registry of Myocardial Infarction (NRMI) 4b-5, was evaluated using multivariable-adjusted logistic regression models. Mean LDL-C was 104 ± 38, HDL-C was 41 ± 14, and triglycerides 143 ± 83 mg/dl. Compared with the lowest quartile of LDL-C (<77 mg/dl), the risk of in-hospital mortality in the second to fourth quartiles was decreased (adjusted odds ratio 0.79, 0.80, and 0.85, respectively). For HDL-C, only those in the lowest quartile (<31 mg/dl) had higher risk of in-hospital mortality (odds ratio 1.20) compared with the highest quartile (≥47 mg/dl). Results from NRMI 4b-5 suggest a lipid paradox, with lower LDL-C levels associated with increased risk of in-hospital mortality, contrary to findings outside the acute setting. Consistent with previous analyses, lowest HDL-C levels were associated with increased in-hospital mortality. In conclusion, further explorations of the relationship between very low levels of LDL-C, myocardial necrosis, and subsequent adverse cardiovascular events are warranted.


Subject(s)
Cholesterol, HDL/blood , Cholesterol, LDL/blood , Hospital Mortality , Myocardial Infarction/blood , Myocardial Infarction/mortality , Acute-Phase Reaction/blood , Aged , Aged, 80 and over , Cohort Studies , Databases, Factual , Female , Hospitalization/statistics & numerical data , Humans , Logistic Models , Male , Middle Aged , Risk Factors , Triglycerides/blood , United States
6.
BMC Cardiovasc Disord ; 13: 86, 2013 Oct 16.
Article in English | MEDLINE | ID: mdl-24131509

ABSTRACT

BACKGROUND: Central venous catheter (CVC) and hemodialysis (HD) catheter usage are associated with complications that occur during catheter insertion, dwell period, and removal. This study aims to identify and describe the incidence rates of catheter-related complications in a large patient population in a United States-based health care claims database after CVC or HD catheter placement. METHODS: Patients in the i3 InVision DataMart® health care claims database with at least 1 CVC or HD catheter insertion claim were categorized into CVC or HD cohorts using diagnostic and procedural codes from the US Renal Data System, American College of Surgeons, and American Medical Association's Physician Performance Measures. Catheter-related complications were identified using published diagnostic and procedural codes. Incidence rates (IRs)/1000 catheter-days were calculated for complications including catheter-related bloodstream infections (CRBSIs), thrombosis, embolism, intracranial hemorrhage (ICH), major bleeding (MB), and mechanical catheter-related complications (MCRCs). RESULTS: Thirty percent of the CVC cohort and 54% of the HD cohort had catheter placements lasting <90 days. Catheter-related complications occurred most often during the first 90 days of catheter placement. IRs were highest for CRBSIs in both cohorts (4.0 [95% CI, 3.7-4.3] and 5.1 [95% CI, 4.7-5.6], respectively). Other IRs in CVC and HD cohorts, respectively, were thrombosis, 1.3 and 0.8; MCRCs, 0.6 and 0.7; embolism, 0.4 and 0.5; MB, 0.1 and 0.3; and ICH, 0.1 in both cohorts. Patients with cancer at baseline had significantly higher IRs for CRBSIs and thrombosis than non-cancer patients. CVC or HD catheter-related complications were most frequently seen in patients 16 years or younger. CONCLUSIONS: The risk of catheter-related complications is highest during the first 90 days of catheter placement in patients with CVCs and HD catheters and in younger patients (≤16 years of age) with HD catheters. Data provided in this study can be applied toward improving patient care.


Subject(s)
Catheter-Related Infections/epidemiology , Central Venous Catheters/adverse effects , Cross Infection/epidemiology , Insurance Claim Review , Renal Dialysis/adverse effects , Thrombosis/epidemiology , Adolescent , Adult , Aged , Catheter-Related Infections/diagnosis , Child , Child, Preschool , Cohort Studies , Cross Infection/diagnosis , Female , Humans , Incidence , Infant , Male , Middle Aged , Retrospective Studies , Thrombosis/diagnosis , Young Adult
7.
Am J Cardiol ; 111(12): 1694-700, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23528029

ABSTRACT

Patients with acute coronary syndromes have a substantial disease burden and are at continued risk of future cardiovascular events. In this setting, the relation between previous myocardial infarction (MI) and the risk of subsequent in-hospital adverse cardiovascular outcomes has not been definitively established. The data were analyzed from 427,778 hospitalized patients presenting with acute MI from July 2002 to December 2006, who were enrolled in the National Registry of Myocardial Infarction 4-5 study. Multivariate logistic regression models were developed to examine the association between a history of MI and in-hospital all-cause mortality, recurrent MI, and congestive heart failure/pulmonary edema. Covariate adjustments were made for demographic characteristics, co-morbidities, prearrival medications, and health status at presentation. Similarly, multivariate linear regression models were used to evaluate the length of stay. Of the 232,927 patients with acute MI included in the present study after exclusions, 24.7% reported a history of MI. In-hospital mortality was not significantly different between the patients with and without a history of MI (adjusted odds ratio 0.99, 95% confidence interval 0.95 to 1.04, p = 0.75). However, patients with a previous MI had a small increased risk of in-hospital recurrent MI (adjusted odds ratio 1.18, 95% confidence interval 1.08 to 1.29, p <0.001) and congestive heart failure/pulmonary edema (adjusted odds ratio 1.23, 95% confidence interval1.19 to 1.28, p <0.001) compared with patients with no history of MI. In conclusion, a history of MI did not significantly affect in-hospital mortality after admission for an acute MI.


Subject(s)
Heart Failure/etiology , Heart Failure/mortality , Hospital Mortality , Inpatients , Myocardial Infarction/complications , Myocardial Infarction/mortality , Aged , Aged, 80 and over , Female , Heart Failure/drug therapy , Humans , Male , Middle Aged , Myocardial Infarction/etiology , Prognosis , Registries , Retrospective Studies , Risk Assessment , Risk Factors
8.
Thromb Res ; 130(3): 381-9, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22658414

ABSTRACT

BACKGROUND: The assessment of patients with suspected deep vein thrombosis (DVT) remains challenging despite current diagnostic algorithms. (99m)Tc-labelled DI-DD3B6/22-80B3 Fab´ fragments ((99m)Tc-DI-80B3, ThromboView®) is a novel diagnostic test that uses a radiolabelled humanized monoclonal antibody fragment specific for the D-dimer region of cross-linked fibrin to detect DVT. This test has an anatomic component to locate DVT and a functional component to differentiate acute (newly formed) thrombus from inactive (old) thrombus. METHODS: In a multi-centre prospective cohort trial we investigated the diagnostic accuracy and safety of (99m)Tc-DI-80B3 in consecutive patients with suspected DVT who had the diagnosis confirmed or excluded by venography. RESULTS: We enrolled 94 patients with suspected DVT of whom 12 did not have (99m)Tc-DI-80B3 imaging, leaving 82 patients for the safety analysis. Of these patients, there were 16 with non-evaluable imaging (11 venography, 7 (99m)Tc-DI-80B3, both in two patients) leaving 66 patients for the accuracy analysis. (99m)Tc-DI-80B3 imaging was well-tolerated: 2 patients developed urticaria; none developed serious adverse events. For proximal DVT, the sensitivity (84.2%; 95% confidence interval [CI]: 62.4-94.5) and specificity (97.6%; CI: 83.3-99.4) were highest when the combined 0.25-hour and 3-hour (99m)Tc-DI-80B3 images were used. The accuracy was lower for distal DVT, irrespective of the images used. There were insufficient patients to comment on the accuracy of (99m)Tc-DI-80B3 imaging for suspected recurrent DVT. CONCLUSIONS: (99m)Tc-DI-80B3 (ThromboView®) is a novel diagnostic modality for patients with suspected DVT with a promising accuracy and safety profile that justifies additional clinical development in diagnostic accuracy and clinical management studies.


Subject(s)
Antibodies, Monoclonal , Fibrin Fibrinogen Degradation Products/immunology , Image Interpretation, Computer-Assisted/methods , Positron-Emission Tomography/methods , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/immunology , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/immunology , Cohort Studies , Female , Humans , Immunoglobulin Fab Fragments/adverse effects , Immunoglobulin Fab Fragments/immunology , Isotope Labeling , Male , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/immunology , Reproducibility of Results , Sensitivity and Specificity
9.
Clin Nephrol ; 77(1): 55-61, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22185969

ABSTRACT

BACKGROUND: We evaluated the efficacy and safety of the thrombolytic agent tenecteplase for the treatment of dysfunctional hemodialysis (HD) catheters. METHODS: Data were pooled from 2 Phase III clinical studies: the randomized, placebo-controlled TROPICS 3 trial and the open-label TROPICS 4 trial. Eligible patients received either an initial dose of tenecteplase (2 mg/lumen) or placebo (TROPICS 3 only) for a 1-h intracatheter dwell. Treatment success was defined as blood flow rate (BFR) ≥ 300 ml/min and a ≥ 25 ml/min increase from baseline BFR, without line reversal, 30 min before and at the end of HD. All TROPICS 4 patients and the TROPICS 3 patients enrolled after the final protocol amendment without treatment success received an instillation of tenecteplase at the end of the initial visit for an extended dwell of up to 72 h. RESULTS: A total of 372 patients with dysfunctional catheters were enrolled in the 2 studies. Of the 297 patients treated with tenecteplase at the initial visit, 31% achieved treatment success, with a mean (SD) change from baseline BFR of 73 (120) ml/min. Among the 179 patients who received a 1-h dwell of study drug followed by extended-dwell tenecteplase, 46% had treatment success at the end of the next HD session. Six catheter-related bloodstream infections and 2 thromboses were reported in patients following tenecteplase exposure. CONCLUSION: Tenecteplase, administered as a 1-h dwell or a 1-h dwell followed by an extended dwell, was associated with improved BFR in dysfunctional HD catheters in the TROPICS 3 and 4 clinical trials.


Subject(s)
Fibrinolytic Agents/administration & dosage , Graft Occlusion, Vascular/prevention & control , Kidney Failure, Chronic/therapy , Regional Blood Flow/drug effects , Renal Dialysis , Tissue Plasminogen Activator/administration & dosage , Aged , Clinical Trials, Phase III as Topic/statistics & numerical data , Female , Fibrinolytic Agents/adverse effects , Humans , Male , Middle Aged , Randomized Controlled Trials as Topic/statistics & numerical data , Tenecteplase , Tissue Plasminogen Activator/adverse effects
10.
J Vasc Interv Radiol ; 22(8): 1117-23, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21570873

ABSTRACT

PURPOSE: To evaluate, in a phase III, single-arm study, the safety and efficacy of the thrombolytic agent tenecteplase in restoring function to dysfunctional central venous catheters (CVCs). MATERIALS AND METHODS: Pediatric and adult patients with dysfunctional CVCs were eligible to receive as much as 2 mL (2 mg) of intraluminal tenecteplase, which was left to dwell in the CVC lumen for a maximum of 120 minutes. If CVC function was not restored at 120 minutes, a second dose was instilled for an additional 120 minutes. RESULTS: Tenecteplase was administered to 246 patients. Mean patient age was 44 years (range, 0-92 y); 72 patients (29%) were younger than 17 years of age. Chemotherapy was the most common reason for catheter insertion. Restoration of CVC function was achieved in 177 patients (72%) within 120 minutes after the first dose. After instillation of a maximum of two doses of tenecteplase, CVC function was restored in 200 patients (81%), with similar frequencies in pediatric (83%) and adult (80%) patients. Adverse events (AEs) were reported in 31 patients (13%); fever (2%), neutropenia (1%), and nausea (0.8%) were most common. One serious AE, an allergic hypersensitivity reaction, was judged to be related to tenecteplase and/or a chemotherapeutic agent that the patient was receiving concurrently. CONCLUSIONS: Consecutive administration of one or two doses of tenecteplase into CVCs showed efficacy in the restoration of catheter function in patients with dysfunctional CVCs.


Subject(s)
Catheterization, Central Venous/adverse effects , Fibrinolytic Agents/administration & dosage , Tissue Plasminogen Activator/administration & dosage , Adolescent , Adult , Aged , Catheters, Indwelling , Child , Child, Preschool , Equipment Failure , Female , Humans , Infant , Male , Middle Aged , Tenecteplase , Treatment Outcome
11.
J Thromb Thrombolysis ; 31(1): 99-106, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20623319

ABSTRACT

Hemodialysis (HD) catheters are prone to thrombotic occlusion. We evaluated tenecteplase, a thrombolytic, for the treatment of dysfunctional HD catheters. Patients with tunneled HD catheters and blood flow rate (BFR) <300 mL/min received open-label tenecteplase (2 mg/lumen) for a 1 h intracatheter dwell. Treatment success was defined as BFR ≥ 300 mL/min and a ≥ 25 mL/min increase from baseline BFR, 30 min before and at the end of HD. Patients without treatment success at the end of the initial visit received another 2 mg dose of tenecteplase for an up to 72 h extended dwell. Of 223 enrolled patients, 34% (95% confidence interval [CI], 28-40%) had treatment success after a 1 h dwell. Mean (standard deviation [SD]) BFR change from baseline was 82 (124) mL/min. Treatment success in those who received extended-dwell tenecteplase (n = 116) was 49% (95% CI, 40-58%), with mean (SD) BFR change from baseline of 117 (140) mL/min. Reported targeted adverse events included five catheter-related bloodstream infections and one thrombosis. No intracranial hemorrhage, major bleeding, embolic events, or catheter-related complications were reported. Tenecteplase administered as a 1 h or 1 h plus extended dwell was associated with improved HD catheter function in the TROPICS 4 trial.


Subject(s)
Catheters , Fibrinolytic Agents/administration & dosage , Renal Dialysis/methods , Tissue Plasminogen Activator/administration & dosage , Adolescent , Adult , Aged , Aged, 80 and over , Female , Fibrinolytic Agents/adverse effects , Humans , Male , Middle Aged , Tenecteplase , Time Factors , Tissue Plasminogen Activator/adverse effects
12.
J Vasc Interv Radiol ; 21(12): 1852-8, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21111365

ABSTRACT

PURPOSE: To evaluate the efficacy and safety of the thrombolytic tenecteplase, a fibrin-specific recombinant tissue plasminogen activator, for restoring function to dysfunctional central venous catheters (CVCs). MATERIALS AND METHODS: In this double-blind, placebo-controlled study, eligible patients with dysfunctional nonhemodialysis CVCs were randomly assigned to two treatment arms. In the first arm (TNK-TNK-PBO), patients received an initial dose of intraluminal tenecteplase (TNK) (up to 2 mg), a second dose of tenecteplase if indicated, and a third placebo (PBO) dose. In the PBO-TNK-TNK arm, placebo was instilled first followed by up to two doses of tenecteplase, if needed, for restoration of catheter function. After administration of each dose, CVC function was assessed at 15, 30, and 120 minutes. RESULTS: There were 97 patients who received either TNK-TNK-PBO (n = 50) or PBO-TNK-TNK (n = 47). Within 120 minutes of initial study drug instillation, catheter function was restored to 30 patients (60%) in the TNK-TNK-PBO arm and 11 patients (23%) in the PBO-TNK-TNK arm, for a treatment difference of 37 percentage points (95% confidence interval 18-55; P = .0002). Cumulative restoration rates for CVC function increased to 87% after the second dose of tenecteplase in both study arms combined. Two patients developed a deep vein thrombosis (DVT) after exposure to tenecteplase; one DVT was considered to be drug related. No cases of intracranial hemorrhage, major bleeding, embolic events, catheter-related bloodstream infections, or catheter-related complications were reported. CONCLUSIONS: Tenecteplase was efficacious for restoration of catheter function in these study patients with dysfunctional CVCs.


Subject(s)
Catheterization, Central Venous/adverse effects , Catheters, Indwelling/adverse effects , Fibrinolytic Agents/administration & dosage , Thrombolytic Therapy , Thrombosis/drug therapy , Tissue Plasminogen Activator/administration & dosage , Adolescent , Adult , Aged , Catheterization, Central Venous/instrumentation , Chi-Square Distribution , Double-Blind Method , Female , Fibrinolytic Agents/adverse effects , Humans , Male , Middle Aged , Placebo Effect , Regional Blood Flow , Tenecteplase , Thrombolytic Therapy/adverse effects , Thrombosis/etiology , Thrombosis/physiopathology , Time Factors , Tissue Plasminogen Activator/adverse effects , Treatment Outcome , United States , Young Adult
13.
Clin J Am Soc Nephrol ; 5(4): 631-6, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20133491

ABSTRACT

BACKGROUND AND OBJECTIVES: Despite widespread use of tunneled hemodialysis (HD) catheters, their utility is limited by the development of thrombotic complications. To address this problem, this study investigated whether the thrombolytic agent tenecteplase can restore blood flow rates (BFRs) in dysfunctional HD catheters. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this randomized, double-blind study, patients with dysfunctional tunneled HD catheters, defined as a BFR <300 ml/min at -250 mmHg pressure in the arterial line, received 1-hour intracatheter dwell with tenecteplase (2 mg) or placebo. The primary endpoint was the percentage of patients with BFR > or =300 ml/min and an increase of > or =25 ml/min above baseline 30 minutes before and at the end of HD. Safety endpoints included the incidence of hemorrhagic, thrombotic, and infectious complications. RESULTS: Eligible patients (n = 149) were treated with tenecteplase (n = 74) or placebo (n = 75). Mean baseline BFR was similar for the tenecteplase and placebo groups at 151 and 137 ml/min, respectively. After a 1-hour dwell, 22% of patients in the tenecteplase group had functional catheters compared with 5% among placebo controls (P = 0.004). At the end of dialysis, mean change in BFR was 47 ml/min in the tenecteplase group versus 12 ml/min in the placebo group (P = 0.008). Four catheter-related bloodstream infections (one tenecteplase, three placebo) and one thrombosis (tenecteplase) were observed. There were no reports of intracranial hemorrhage, major bleeding, embolic events, or catheter-related complications. CONCLUSIONS: Tenecteplase improved HD catheter function and had a favorable safety profile compared with placebo.


Subject(s)
Catheterization, Central Venous/instrumentation , Catheterization, Peripheral/instrumentation , Catheters, Indwelling , Fibrinolytic Agents/therapeutic use , Renal Dialysis/instrumentation , Thrombosis/drug therapy , Tissue Plasminogen Activator/therapeutic use , Adolescent , Adult , Aged , Blood Flow Velocity , Catheterization, Central Venous/adverse effects , Catheterization, Peripheral/adverse effects , Catheters, Indwelling/adverse effects , Chi-Square Distribution , Double-Blind Method , Female , Fibrinolytic Agents/adverse effects , Humans , Male , Middle Aged , Regional Blood Flow , Renal Dialysis/adverse effects , Renal Dialysis/methods , Tenecteplase , Thrombosis/etiology , Thrombosis/physiopathology , Time Factors , Tissue Plasminogen Activator/adverse effects , Treatment Outcome , United States , Young Adult
14.
J Intensive Care Med ; 23(5): 313-20, 2008.
Article in English | MEDLINE | ID: mdl-18701526

ABSTRACT

We retrospectively evaluated argatroban dosing patterns, clinical outcomes, and the effects of heart failure and multiple organ system failure on dosing requirements in 65 adult, intensive care patients administered argatroban anticoagulation for clinically suspected heparin-induced thrombocytopenia (n=56) or history of heparin-induced thrombocytopenia (n=9). Argatroban was initiated then titrated to achieve target activated partial thromboplastin times 1.5 to 3 times normal control (ie, 42-84 seconds). Overall, argatroban was initiated at 1.14+/-0.62 microg/kg/min (mean+/-SD) and administered for 11.4+/-9.5 days, with comparable dosing patterns between patients with suspected, versus previous, heparin-induced thrombocytopenia. Sixty-four (98.5%) patients achieved target activated partial thromboplastin times, typically following no or one dose adjustment. Therapeutic doses were lower in patients with, versus without, heart failure (0.58+/-0.28 vs 0.97+/-0.6 microg/kg/min, P= .042) and decreased as the number of failed organ systems increased from 1 to 2 to =3 (1.10+/-0.67 vs 0.87+/-0.47 vs 0.58+/-0.47 microg/kg/min, P= .008). From argatroban initiation until patient discharge or death, 11 (16.9%) patients (3 off argatroban) developed thromboembolic complications; 14 (21.5%) died (11 off argatroban, 7 from multiple organ system failure); and 1 (1.5%) required amputation. Nine patients (13.8%) experienced bleeding, none fatal. This experience suggests that argatroban administered at approximately 1 micro/kg/min provides adequate levels of anticoagulation in many intensive care unit patients with suspected or previous heparin-induced thrombocytopenia. Reduced doses are needed when heart failure or multiple organ system failure is present.


Subject(s)
Anticoagulants/administration & dosage , Critical Care , Heart Failure/complications , Multiple Organ Failure/complications , Pipecolic Acids/administration & dosage , Thrombocytopenia/drug therapy , Aged , Arginine/analogs & derivatives , Cohort Studies , Dose-Response Relationship, Drug , Female , Heart Failure/blood , Heart Failure/therapy , Heparin/adverse effects , Humans , Male , Middle Aged , Multiple Organ Failure/blood , Multiple Organ Failure/therapy , Retrospective Studies , Sulfonamides , Thrombocytopenia/chemically induced , Thrombocytopenia/complications , Treatment Outcome
15.
Am J Cardiol ; 100(7): 1087-9, 2007 Oct 01.
Article in English | MEDLINE | ID: mdl-17884367

ABSTRACT

Left main (LM) coronary disease, carotid artery disease, and peripheral arterial disease each reflects advanced atherosclerosis. The frequency of their coexistence in the same patient has not been fully elucidated. All coronary angiograms obtained at the Cleveland Clinic from November 2003 to October 2005 were analyzed for presence of LM stenosis > or =50%. Patients with previous coronary artery bypass graft surgery were excluded. Patients with available carotid ultrasound and ankle-brachial indexes formed the analysis cohorts. A total of 10,298 coronary angiograms were obtained in 9,715 patients. There were 186 patients with LM disease and 1,913 patients without LM disease with carotid artery ultrasound data. There were 29 patients with LM disease and 604 patients without LM disease with available ankle-brachial indexes. Patients with significant LM disease more frequently had associated carotid stenosis > or =60% compared with patients without LM disease (31.2% vs 15.2%, p <0.0001). Patients with LM disease had lower mean ankle-brachial indexes compared with patients without LM disease (0.78 vs 0.87, p = 0.042). In conclusion, compared with patients without LM disease, patients with LM disease have a higher burden of advanced atherosclerosis as evidenced by a higher prevalence of significant carotid stenosis and lower ankle-brachial indexes.


Subject(s)
Carotid Artery Diseases/epidemiology , Carotid Stenosis/epidemiology , Coronary Artery Disease/epidemiology , Coronary Stenosis/epidemiology , Peripheral Vascular Diseases/epidemiology , Carotid Artery Diseases/complications , Carotid Artery Diseases/diagnostic imaging , Carotid Stenosis/diagnostic imaging , Carotid Stenosis/etiology , Coronary Angiography , Coronary Artery Disease/complications , Coronary Artery Disease/diagnostic imaging , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/etiology , Female , Humans , Male , Peripheral Vascular Diseases/complications , Peripheral Vascular Diseases/diagnosis , Ultrasonography
16.
Cleve Clin J Med ; 73 Suppl 4: S22-9, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17385388

ABSTRACT

A variety of diagnostic methods for peripheral arterial disease (PAD) are available, each with strengths and limitations. The ankle-brachial index is a simple and useful screening tool for PAD that can be performed in the office setting. Segmental limb pressure examinations and pulse volume recordings aid in identifying the location of disease. Pulse volume recordings are especially useful, along with the ankle-brachial index, in assessing functional status during exercise. Duplex ultrasonography, magnetic resonance angiography, and computed tomographic angiography are helpful in providing anatomic detail and thus yield additional information for planning interventional therapy. Conventional angiography, the "gold standard" study for PAD diagnosis, is now usually pursued only once an intervention is planned.


Subject(s)
Peripheral Vascular Diseases/diagnosis , Ankle/blood supply , Blood Pressure/physiology , Brachial Artery/physiology , Diagnostic Imaging , Exercise Test , Humans
17.
Cleve Clin J Med ; 72 Suppl 1: S31-6, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15853177

ABSTRACT

Heparin-induced thrombocytopenia (HIT) is a potentially devastating complication of therapy with either unfractionated or low-molecular-weight heparin. Thrombocytopenia is no longer essential for the diagnosis of HIT, since a 50% drop in the platelet count may be a more specific indicator. Once HIT is clinically suspected, heparin should be stopped immediately and direct thrombin inhibitor therapy started; waiting for laboratory confirmation may be catastrophic.


Subject(s)
Anticoagulants/adverse effects , Heparin/adverse effects , Hirudins/analogs & derivatives , Thrombocytopenia/chemically induced , Anticoagulants/administration & dosage , Arginine/analogs & derivatives , Heparin/administration & dosage , Heparin, Low-Molecular-Weight/administration & dosage , Heparin, Low-Molecular-Weight/adverse effects , Hirudins/administration & dosage , Humans , Pipecolic Acids/administration & dosage , Pipecolic Acids/therapeutic use , Platelet Count , Practice Guidelines as Topic , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Risk Assessment , Sulfonamides , Thrombocytopenia/diagnosis , Thrombocytopenia/prevention & control , Time Factors
18.
Med Clin North Am ; 87(6): 1179-87, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14680299

ABSTRACT

A 58-year-old woman presents with headache, mental status changes, and new-onset generalized seizures. MRI of the brain reveals a frontoparietal enhancing mass lesion suggestive of glioblastoma multiforme. Craniotomy for diagnosis, debulking, and likely placement of chemotherapy-impregnated wafers is planned. Venous thromboprophylaxis is prescribed.


Subject(s)
Brain Neoplasms/drug therapy , Brain Neoplasms/surgery , Craniotomy , Fibrinolytic Agents/administration & dosage , Glioblastoma/drug therapy , Glioblastoma/surgery , Venous Thrombosis/prevention & control , Animals , Brain Neoplasms/diagnosis , Drug Delivery Systems , Female , Glioblastoma/diagnosis , Humans , Intraoperative Care
20.
J Thromb Thrombolysis ; 13(3): 183-5, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12355036

ABSTRACT

Outpatient treatment of deep venous thrombosis has gained widespread acceptance and is facilitated by the use of subcutaneous low molecular weight heparins (LMWH). We report two patients in whom subcutaneous lepirudin was used for long term anticoagulation after heart transplant or surgical pulmonary embolectomy because treatment with LMWH or warfarin was contraindicated, unsuccessful, or impractical. Neither bleeding complications nor recurrent thromboses developed. Subcutaneous lepirudin may be safely and effectively employed for the outpatient treatment of venous thrombosis in selected cases including patients with heparin-induced thrombocytopenia and in those who fail LMWH.


Subject(s)
Ambulatory Care/methods , Anticoagulants/administration & dosage , Hirudins/analogs & derivatives , Hirudins/administration & dosage , Recombinant Proteins/administration & dosage , Thromboembolism/prevention & control , Venous Thrombosis/prevention & control , Adult , Embolectomy/adverse effects , Heart Transplantation/adverse effects , Humans , Injections, Subcutaneous , Male , Postoperative Complications/drug therapy , Postoperative Complications/prevention & control , Pulmonary Embolism/complications , Pulmonary Embolism/surgery , Thromboembolism/drug therapy , Thromboembolism/etiology , Treatment Outcome , Venous Thrombosis/drug therapy , Venous Thrombosis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...